2025 Q4 -tulosraportti
29 päivää sitten
‧49 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 202 | - | - | ||
| 111 | - | - | ||
| 485 | - | - | ||
| 92 | - | - | ||
| 116 | - | - |
Ylin
26,75VWAP
Alin
25,3VaihtoMäärä
0,8 31 502
VWAP
Ylin
26,75Alin
25,3VaihtoMäärä
0,8 31 502
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 31 502 | 31 502 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 31 502 | 31 502 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 28.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 5.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 16.7.2025 | ||
2025 Q1 -tulosraportti 6.5.2025 | ||
2024 Q4 -tulosraportti 6.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·2 päivää sittenGood News! Now Orexo can more easily work to secure partner agreements. No debts! Hoping for exciting and positive news on R&D day 24/3! The presentation of Amorphox and the new strategy (become drug delivery company) is estimated to take 3 hours! Book yourselves in to listen! I believe OX124 will be sold to Dexcel! Why would they only settle for Zubsolv? Pharmaceutical company Orexo calls for early redemption of its outstanding senior secured social bonds 2024/2028 of 500 million kronor, according to a press release. The redemption will take place at a price of 103.25 percent of the nominal amount, plus accrued and unpaid interest up to and including the settlement date, which is March 30. In connection with the early redemption, the bonds will be delisted from Nasdaq Stockholm's list for sustainable bonds.- ·26.2.New institutional owners in Holdings and on the company's website. Bank of Montreal owns 779K
·23.2.It would be interesting to understand why Morgan Stanley trades Orexo on and off around the 5 % disclosure threshold. Do they want to create an appearance of activity with these constant disclosures? At least they are not operating in secret.- ·16.2.Comments by JS: I believe Dexcel Pharma (besides Zubsolv) is after OX124 (acute medication for overdoses). This medication can be compared to Narcan, which is currently on the market and sold for several billion SEK over-the-counter! Orexo should get at least 1 billion upfront + royalty for OX124 in a so-called partnership. Expected to be submitted to the FDA in summer 2026. The second major revenue opportunity in the pipeline is OX640, an acute medication for allergic reactions. OX640 – intranasal powder-based adrenaline for allergic reactions, incl. anaphylaxis – CLINICAL PHASE Project in brief The goal with OX640 is to develop a powder-based intranasal adrenaline medication for acute treatment of allergic reactions, including anaphylaxis. Adrenaline is a very unstable active ingredient that is sensitive to chemical degradation, especially when exposed to elevated temperatures, which is why the majority of today's commercial adrenaline products have limited shelf life and restrictive storage requirements. Differentiation and IP OX640 is a needle-free adrenaline medication based on AmorphOX technology. Supported by the technology, adrenaline has been formulated together with carrier material and then spray-dried to develop an AmorphOX powder suitable for intranasal administration. Powder-based medications, unlike liquid-based ones, can better maintain chemical and physical stability of the substance. Improved stability extends shelf life, preserves therapeutic effect over time, increases storage flexibility, and eliminates the need for preservatives. These factors can provide significant benefits for patients and healthcare systems worldwide. OX640 has patents and patent applications protecting the product until 2044 Peers: ARS Pharma received MUSD150 upfront for Neffy (NOTE not USA). The medication is already on the market and shows good growth. There has already been speculation about agreements in 2025, but given the sale of Zubsolv and the strong financial position, Orexo now wants to take this project a bit further before bringing in a partner. Likely because they see greater value in the future after more studies as proof. Let's say Orexo closes deals for these 2 medications in 2H 2026, then we're perhaps talking about 2 billion in upfront. Given the valuation of 930 mkr with a cash position of 500 mkr, I see at least a doubling of the share price, i.e., >60 kr. Furthermore, there are opportunities for nasal Semagluid (potential partner = Novo N), Vaccines (Abera et al.) etc. The Amorphox platform is a potential goldmine, but the company must now prove that it can commercialize it. I believe many positive news will come during 2026. An important date is March 24, when the company will present its new strategy. Orexo is on its way to transforming into a so-called Drug-delivery company. Carnegie has set a target price of 35-42 kr (conservative analysis) but has not taken future pipeline into account! NOTE Novo H owns 28% of Orexo. No way they'd let anyone other than Novo N in if they're betting on nasal insulin.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
29 päivää sitten
‧49 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sittenGood News! Now Orexo can more easily work to secure partner agreements. No debts! Hoping for exciting and positive news on R&D day 24/3! The presentation of Amorphox and the new strategy (become drug delivery company) is estimated to take 3 hours! Book yourselves in to listen! I believe OX124 will be sold to Dexcel! Why would they only settle for Zubsolv? Pharmaceutical company Orexo calls for early redemption of its outstanding senior secured social bonds 2024/2028 of 500 million kronor, according to a press release. The redemption will take place at a price of 103.25 percent of the nominal amount, plus accrued and unpaid interest up to and including the settlement date, which is March 30. In connection with the early redemption, the bonds will be delisted from Nasdaq Stockholm's list for sustainable bonds.
- ·26.2.New institutional owners in Holdings and on the company's website. Bank of Montreal owns 779K
- ·23.2.It would be interesting to understand why Morgan Stanley trades Orexo on and off around the 5 % disclosure threshold. Do they want to create an appearance of activity with these constant disclosures? At least they are not operating in secret.
- ·16.2.Comments by JS: I believe Dexcel Pharma (besides Zubsolv) is after OX124 (acute medication for overdoses). This medication can be compared to Narcan, which is currently on the market and sold for several billion SEK over-the-counter! Orexo should get at least 1 billion upfront + royalty for OX124 in a so-called partnership. Expected to be submitted to the FDA in summer 2026. The second major revenue opportunity in the pipeline is OX640, an acute medication for allergic reactions. OX640 – intranasal powder-based adrenaline for allergic reactions, incl. anaphylaxis – CLINICAL PHASE Project in brief The goal with OX640 is to develop a powder-based intranasal adrenaline medication for acute treatment of allergic reactions, including anaphylaxis. Adrenaline is a very unstable active ingredient that is sensitive to chemical degradation, especially when exposed to elevated temperatures, which is why the majority of today's commercial adrenaline products have limited shelf life and restrictive storage requirements. Differentiation and IP OX640 is a needle-free adrenaline medication based on AmorphOX technology. Supported by the technology, adrenaline has been formulated together with carrier material and then spray-dried to develop an AmorphOX powder suitable for intranasal administration. Powder-based medications, unlike liquid-based ones, can better maintain chemical and physical stability of the substance. Improved stability extends shelf life, preserves therapeutic effect over time, increases storage flexibility, and eliminates the need for preservatives. These factors can provide significant benefits for patients and healthcare systems worldwide. OX640 has patents and patent applications protecting the product until 2044 Peers: ARS Pharma received MUSD150 upfront for Neffy (NOTE not USA). The medication is already on the market and shows good growth. There has already been speculation about agreements in 2025, but given the sale of Zubsolv and the strong financial position, Orexo now wants to take this project a bit further before bringing in a partner. Likely because they see greater value in the future after more studies as proof. Let's say Orexo closes deals for these 2 medications in 2H 2026, then we're perhaps talking about 2 billion in upfront. Given the valuation of 930 mkr with a cash position of 500 mkr, I see at least a doubling of the share price, i.e., >60 kr. Furthermore, there are opportunities for nasal Semagluid (potential partner = Novo N), Vaccines (Abera et al.) etc. The Amorphox platform is a potential goldmine, but the company must now prove that it can commercialize it. I believe many positive news will come during 2026. An important date is March 24, when the company will present its new strategy. Orexo is on its way to transforming into a so-called Drug-delivery company. Carnegie has set a target price of 35-42 kr (conservative analysis) but has not taken future pipeline into account! NOTE Novo H owns 28% of Orexo. No way they'd let anyone other than Novo N in if they're betting on nasal insulin.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 202 | - | - | ||
| 111 | - | - | ||
| 485 | - | - | ||
| 92 | - | - | ||
| 116 | - | - |
Ylin
26,75VWAP
Alin
25,3VaihtoMäärä
0,8 31 502
VWAP
Ylin
26,75Alin
25,3VaihtoMäärä
0,8 31 502
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 31 502 | 31 502 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 31 502 | 31 502 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 28.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 5.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 16.7.2025 | ||
2025 Q1 -tulosraportti 6.5.2025 | ||
2024 Q4 -tulosraportti 6.2.2025 |
2025 Q4 -tulosraportti
29 päivää sitten
‧49 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 28.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 5.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 16.7.2025 | ||
2025 Q1 -tulosraportti 6.5.2025 | ||
2024 Q4 -tulosraportti 6.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sittenGood News! Now Orexo can more easily work to secure partner agreements. No debts! Hoping for exciting and positive news on R&D day 24/3! The presentation of Amorphox and the new strategy (become drug delivery company) is estimated to take 3 hours! Book yourselves in to listen! I believe OX124 will be sold to Dexcel! Why would they only settle for Zubsolv? Pharmaceutical company Orexo calls for early redemption of its outstanding senior secured social bonds 2024/2028 of 500 million kronor, according to a press release. The redemption will take place at a price of 103.25 percent of the nominal amount, plus accrued and unpaid interest up to and including the settlement date, which is March 30. In connection with the early redemption, the bonds will be delisted from Nasdaq Stockholm's list for sustainable bonds.
- ·26.2.New institutional owners in Holdings and on the company's website. Bank of Montreal owns 779K
- ·23.2.It would be interesting to understand why Morgan Stanley trades Orexo on and off around the 5 % disclosure threshold. Do they want to create an appearance of activity with these constant disclosures? At least they are not operating in secret.
- ·16.2.Comments by JS: I believe Dexcel Pharma (besides Zubsolv) is after OX124 (acute medication for overdoses). This medication can be compared to Narcan, which is currently on the market and sold for several billion SEK over-the-counter! Orexo should get at least 1 billion upfront + royalty for OX124 in a so-called partnership. Expected to be submitted to the FDA in summer 2026. The second major revenue opportunity in the pipeline is OX640, an acute medication for allergic reactions. OX640 – intranasal powder-based adrenaline for allergic reactions, incl. anaphylaxis – CLINICAL PHASE Project in brief The goal with OX640 is to develop a powder-based intranasal adrenaline medication for acute treatment of allergic reactions, including anaphylaxis. Adrenaline is a very unstable active ingredient that is sensitive to chemical degradation, especially when exposed to elevated temperatures, which is why the majority of today's commercial adrenaline products have limited shelf life and restrictive storage requirements. Differentiation and IP OX640 is a needle-free adrenaline medication based on AmorphOX technology. Supported by the technology, adrenaline has been formulated together with carrier material and then spray-dried to develop an AmorphOX powder suitable for intranasal administration. Powder-based medications, unlike liquid-based ones, can better maintain chemical and physical stability of the substance. Improved stability extends shelf life, preserves therapeutic effect over time, increases storage flexibility, and eliminates the need for preservatives. These factors can provide significant benefits for patients and healthcare systems worldwide. OX640 has patents and patent applications protecting the product until 2044 Peers: ARS Pharma received MUSD150 upfront for Neffy (NOTE not USA). The medication is already on the market and shows good growth. There has already been speculation about agreements in 2025, but given the sale of Zubsolv and the strong financial position, Orexo now wants to take this project a bit further before bringing in a partner. Likely because they see greater value in the future after more studies as proof. Let's say Orexo closes deals for these 2 medications in 2H 2026, then we're perhaps talking about 2 billion in upfront. Given the valuation of 930 mkr with a cash position of 500 mkr, I see at least a doubling of the share price, i.e., >60 kr. Furthermore, there are opportunities for nasal Semagluid (potential partner = Novo N), Vaccines (Abera et al.) etc. The Amorphox platform is a potential goldmine, but the company must now prove that it can commercialize it. I believe many positive news will come during 2026. An important date is March 24, when the company will present its new strategy. Orexo is on its way to transforming into a so-called Drug-delivery company. Carnegie has set a target price of 35-42 kr (conservative analysis) but has not taken future pipeline into account! NOTE Novo H owns 28% of Orexo. No way they'd let anyone other than Novo N in if they're betting on nasal insulin.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 202 | - | - | ||
| 111 | - | - | ||
| 485 | - | - | ||
| 92 | - | - | ||
| 116 | - | - |
Ylin
26,75VWAP
Alin
25,3VaihtoMäärä
0,8 31 502
VWAP
Ylin
26,75Alin
25,3VaihtoMäärä
0,8 31 502
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 31 502 | 31 502 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 31 502 | 31 502 | 0 | 0 |